Breedveld, Ferdinand C.; Leiden University Medical Centre (The Netherlands) > Department of Rheumatology
Emery, Paul; University of Leeds
Bardin, Thomas; Lariboisière Hospital (Paris, France) > Department of Rheumatology
Goel, Niti; UCB (Smyrna, GA)
Ethgen, Dominique J.; Medimmune Inc. (Gaithersburg, MD, USA)
Avouac, Bernard P.; Henri Mondor Hospital (Creteil, France) > Department of Rheumatology
Durez, Patrick; Université Catholique de Louvain (UCL) > Department of Rheumatology
Flamion, Bruno; Facultés Universitaires Notre-Dame de la Paix (FUNDP) > Physiology and Pharmacology Department
Laslop, Andrea; AGES PharmMed Institute Science and Information (Vienna, Austria)
Miossec, Pierre; University of Lyon (France) > Edouard Herriot Hospital > Department of Immunology and Rheumatology, Clinical Immunology Unit
Reiter, Suzanne; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn (German)
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
EMEA. CPMP Points to consider on clinical investigation of medicinal products other than NSAIDs for the treatment of rheumatoid arthritis. 2003. CPMP/EWP/556/95 rev 1/Final. [cited 13 September 2009]; http://www.emea.europa.eu/pdfs/human/ewp/055695en.pdf.2003.
Smolen JS, Aletaha D, Bijlsma JWJ et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
Van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34(Suppl. 2): 74-8.
Smolen JS, Aletaha D, Koeller M, Weisman M, Emery P. New therapies for the treatment of rheumatoid arthritis. Lancet 2007;370:1861-4.
Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
EMEA. Guideline on the choice of the non-inferiority margin. 2006, EMEA/CPMP/EWP/2158/99 [cited 31 October 2009]; http://www.emea.europa.eu/pdfs/human/ewp/215899en.pdf.
Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68:1094-9.
Keystone EC, Genovese MC, Klareskog L et al. Golimumab, a human antibody to tumour necrosis factor-α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68: 789-96.
Boers M. A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals. Ann Rheum Dis 2010;69:4-6.
van Vollenhoven RF, Ernestam S, Geborek P et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (SWEFOT trial): 1-year results of a randomised trial. Lancet 2009;374: 459-66.
Bruynesteyn K, Landewe R, van der Linden S, van der Heijde D. Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up. Ann Rheum Dis 2004;63:1413-8.
Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
Landewe R, van der Heijde D. Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. Arthritis Rheum 2004;5: 699-706.
Aletaha D, Strand V, Smolen JS, Ward MM. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43.
Aletaha D, Landewe R, Karonitsch T et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 2008;59:1371-7.
Aletaha D, Landewe R, Karonitsch T et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360-4.
Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism preliminary definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2010 (in press).
Aletaha D, Neogi T, Silman A et al. The 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis. Ann Rheum Dis 2010;69:1580-8.
Aletaha D, Neogi T, Silman A et al. The 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis. Arthritis Rheum 2010;62:2569-81.
Arnett FC, Edworthy SM, Block DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
